{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T14:55:40Z","timestamp":1780671340140,"version":"3.54.1"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Thomas Mackey Center for Infectious Disease Research"},{"name":"Ascension St. John Hospital Department of Medicine"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate the activity of fosfomycin against a group of MRSA strains, including isolates with reduced susceptibility or resistance to vancomycin, daptomycin, linezolid and ceftaroline and to determine the effect of combining various combinations of antimicrobial agents used in the therapy of serious Gram-positive infections.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Broth microdilution testing was used to determine the MICs of fosfomycin, vancomycin, daptomycin, linezolid, ceftaroline and cefazolin. Isolates were selected for further evaluations to determine in vitro synergy between fosfomycin and select antimicrobial agents using chequerboard broth microdilution testing. Fosfomycin was tested in combination with vancomycin, linezolid, daptomycin, ceftaroline and cefazolin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Fosfomycin maintained activity against 100% of strains of vancomycin-resistant Staphylococcus aureus (VRSA) and linezolid-resistant S. aureus (LRSA), 86% of VISA and 95% of daptomycin-resistant S. aureus (DRSA) strains. The combination of fosfomycin with ceftaroline consistently demonstrated synergy among all 18 isolates against the strains tested. The next most potent combination regimen was linezolid with fosfomycin, which demonstrated synergy in 16 of the 18 strains. Daptomycin demonstrated synergy in only 7 of the 18 strains tested when combined with fosfomycin. Cefazolin demonstrated synergy in 6 of 6 strains and vancomycin demonstrated no interaction in 6 of 6 strains tested.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Fosfomycin demonstrated excellent activity against MRSA as well as isolates with resistance or reduced activity to other anti-MRSA drugs including vancomycin, daptomycin and linezolid. When combined with linezolid or daptomycin, fosfomycin demonstrated synergy for all or most strains tested. Thus, these combinations may have potential clinical utility when treating patients with serious infections caused by MRSA.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkac380","type":"journal-article","created":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T20:55:12Z","timestamp":1667076912000},"page":"238-241","source":"Crossref","is-referenced-by-count":26,"title":["<i>In vitro<\/i> activity of fosfomycin alone and in combination against <i>Staphylococcus aureus<\/i> with reduced susceptibility or resistance to methicillin, vancomycin, daptomycin or linezolid"],"prefix":"10.1093","volume":"78","author":[{"given":"Louis D","family":"Saravolatz","sequence":"first","affiliation":[{"name":"Ascension St. John Hospital , Grosse Pointe Woods, MI , USA"},{"name":"Thomas Mackey Center for Infectious Disease Research , Grosse Pointe Woods, MI , USA"},{"name":"Central Michigan University College of Medicine , Mount Pleasant, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Pawlak","sequence":"additional","affiliation":[{"name":"Ascension St. John Hospital , Grosse Pointe Woods, MI , USA"},{"name":"Thomas Mackey Center for Infectious Disease Research , Grosse Pointe Woods, MI , USA"},{"name":"Central Michigan University College of Medicine , Mount Pleasant, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,11,14]]},"reference":[{"key":"2023010801145890200_dkac380-B1","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/cid\/cir034","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2023010801145890200_dkac380-B2","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/jac\/43.2.211","article-title":"In-vitro activity of fosfomycin against vancomycin-resistant enterococci","volume":"43","author":"Allerberger","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"2023010801145890200_dkac380-B3","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing\u2014Thirty-Second Edition: M100","author":"CLSI","year":"2022"},{"key":"2023010801145890200_dkac380-B4","volume-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically\u2014Eleventh Edition: M07","author":"CLSI","year":"2018"},{"key":"2023010801145890200_dkac380-B5","volume-title":"Methods for Determining Bactericidal Activity of Antimicrobial Agents: M-26A","author":"CLSI","year":"1999"},{"key":"2023010801145890200_dkac380-B6","author":"EUCAST"},{"key":"2023010801145890200_dkac380-B7","doi-asserted-by":"crossref","first-page":"e02549-18","DOI":"10.1128\/AAC.02549-18","article-title":"Evaluation of the bactericidal activity of fosfomycin in combination with selected antimicrobial comparison agents tested against Gram-negative bacterial strains by using time-kill curves","volume":"63","author":"Flamm","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2023010801145890200_dkac380-B8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40360-019-0305-y","article-title":"A study on combination of daptomycin with selected antimicrobial agents: in vitro synergistic effect of MIC value of 1\u2005mg\/L against MRSA strains","volume":"20","author":"Lee","year":"2019","journal-title":"BMC Pharmacol Toxicol"},{"key":"2023010801145890200_dkac380-B9","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/jac\/48.2.209","article-title":"In vitro activity of fosfomycin in combination with various antistaphylococcal substances","volume":"48","author":"Grif","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"2023010801145890200_dkac380-B10","doi-asserted-by":"crossref","DOI":"10.1128\/9781555818814","volume-title":"Clinical Microbiology Procedures Handbook","author":"Leber","year":"2016;","edition":"4th ed"},{"key":"2023010801145890200_dkac380-B11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkg301","article-title":"Synergy, antagonism, and what the chequerboard puts between them","volume":"52","author":"Odds","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"2023010801145890200_dkac380-B12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.diagmicrobio.2018.08.010","article-title":"Activity of fosfomycin when tested against US contemporary bacterial isolates","volume":"93","author":"Flamm","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2023010801145890200_dkac380-B13","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jgar.2017.05.022","article-title":"In vitro activity of daptomycin combinations with rifampicin, gentamicin, fosfomycin and fusidic acid against MRSA strains","volume":"10","author":"Aktas","year":"2017","journal-title":"J Glob Antimicrob Resist"},{"key":"2023010801145890200_dkac380-B14","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1093\/cid\/ciaa1081","article-title":"Daptomycin plus fosfomycin versus daptomycin alone for methicillin-resistant Staphylococcus aureus bacteremia and endocarditis: a randomized clinical trial","volume":"72","author":"Pujol","year":"2021","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/1\/238\/48444442\/dkac380.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/1\/238\/48444442\/dkac380.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T01:15:29Z","timestamp":1673140529000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/78\/1\/238\/6827318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,14]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,11,14]]},"published-print":{"date-parts":[[2023,1,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkac380","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1,5]]},"published":{"date-parts":[[2022,11,14]]}}}